IDiyas

For the Inventor, By the Inventor

Xiamen, China

Ying Gu

USPTO Granted Patents = 16

 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 12(Granted Patents)


Location History:

  • Hangzhou, CN (2013 - 2014)
  • Xiamen, CN (2010 - 2022)
  • Fujian, CN (2009 - 2023)

Company Filing History:

goldMedal14 out of 153 
 
Xiamen University
 patents
silverMedal8 out of 15 
 
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
 patents
bronzeMedal8 out of 23 
 
Xiamen Innovax Biotech Co., Ltd.
 patents
where one patent can have more than one assignee

Years Active: 2009-2024

Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 12097251 - Human papilloma virus type 51 L1 protein mutants (2024-09-24),
2. 11771754 - Mutant of L1 protein of human papillomavirus type 18 (2023-10-03),
3. 11213580 - Mutant of L1 protein of human papillomavirus type 16 (2022-01-04),
4. 10940194 - Mutant of L1 protein of human papillomavirus type 58 (2021-03-09),
5. 10537629 - Truncated L1 protein of human papillomavirus type 11 (2020-01-21),
6. 9943586 - Truncated L1 protein of human papillomavirus type 11 (2018-04-17),
7. 9764028 - Fusion protein comprising diphtheria toxin non-toxic mutant CRM197 or fragment thereof (2017-09-19),
8. 9757450 - Fusion protein comprising diphtheria toxin non-toxic mutant CRM197 or fragment thereof (2017-09-12),
9. 9533035 - Truncated L1 protein of human papillomavirus type 11 (2017-01-03),
10. 9512185 - Fusion protein comprising diphtheria toxin non-toxic mutant CRM197 or fragment thereof (2016-12-06),
11. 9428555 - Truncated L1 protein of Human Papillomavirus type 16 (2016-08-30),
12. 9428554 - Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof (2016-08-30),
13. 8715695 - Polypeptide fragments of the hepatitis E virus, the vaccine composition comprising said fragments and the diagnostic kits (2014-05-06),
14. 8524868 - Polypeptide fragments of the hepatitis E virus, the vaccine composition comprising said fragments and the diagnostic kits (2013-09-03),
15. 7786264 - Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof (2010-08-31),

Title: Innovations of Inventor Ying Gu

Introduction

Ying Gu is a prominent inventor based in Xiamen, China, known for his significant contributions to the field of biotechnology. He holds a total of 16 patents, showcasing his innovative work in developing solutions for health-related issues, particularly concerning human papillomavirus (HPV).

Latest Patents

Among his latest patents, Ying Gu has developed a mutated HPV51 L1 protein or a variant thereof. This invention includes a coding sequence, a preparation method, and a virus-like particle that can induce neutralizing antibodies against multiple types of HPV, such as HPV51 and HPV69. This protein and the associated virus-like particle are intended for use in pharmaceutical compositions or vaccines aimed at preventing infections and diseases caused by these HPV types, including cervical cancer and condyloma acuminatum. Another notable patent involves a mutated HPV18 L1 protein, which also targets the generation of neutralizing antibodies against HPV18 and HPV45, with potential applications in preventing related diseases.

Career Highlights

Ying Gu has worked with esteemed institutions, including Xiamen University and Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. His work has significantly advanced the understanding and treatment of HPV-related conditions, contributing to public health initiatives.

Collaborations

Ying Gu has collaborated with notable colleagues such as Shaowei Li and Ningshao Xia, enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Ying Gu's innovative work in the field of biotechnology, particularly concerning HPV, has led to the development of valuable patents that hold promise for improving health outcomes. His contributions continue to influence the landscape of medical research and vaccine development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…